Engitix

Investor: Netherton Investments

Engitix, a biotech company focused on developing therapies for cancer and fibrosis by targeting the extracellular matrix (ECM), has successfully secured £18.6 million in Series A extension funding. This investment is earmarked to accelerate the preclinical development of its proprietary ECM-targeted pipeline and further expand its platform built on one of the largest proprietary ECM datasets.Summary of transaction details:Value: £18.6 millionSector: Biotechnology, Pharmaceuticals, Life SciencesAdvisor: Not specifiedKey Entities: Target: Engitix; Investor: Netherton Investments (investing on behalf of Mike Platt)Location: Not specified in the articleNote: The funding from Netherton Investments reflects a strategic commitment to cutting-edge biotechnological advancements, particularly in leveraging deep data insights into the extracellular matrix for the development of highly targeted therapeutics against challenging diseases like cancer and fibrosis. This investment is crucial for advancing Engitix's preclinical pipeline and expanding its innovative platform.